Minimally invasive surgery for advanced gastric cancer
Laparoscopic and Endoscopic Collaborative Surgery as Rescue-treatment for Advanced Gastric Cancer in Patients Unfit for Surgery - the LE-RACUS Pilot Clinical Study
This study is testing a new, less invasive surgery for older patients with advanced stomach cancer to see if it can help relieve their symptoms and improve their quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Region Stockholm Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Stockholm) |
| Trial ID | NCT06105515 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety and feasibility of Laparoscopic and Endoscopic Collaborative Surgery (LECS) as a less invasive treatment option for patients with advanced gastric cancer who are not candidates for traditional gastrectomy due to age or comorbidities. LECS involves marking the tumor from within using a gastroscope, followed by laparoscopic removal under endoscopic guidance. The goal is to alleviate complications such as bleeding or obstruction caused by the tumor while minimizing surgical trauma. This approach aims to improve the quality of life for frail patients suffering from advanced gastric cancer.
Who should consider this trial
Good fit: Ideal candidates are patients with advanced gastric cancer who are not fit for gastrectomy and have specific tumor characteristics.
Not a fit: Patients with Borrmann type 4 gastric cancer or tumors located in the cardia may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a safer and less invasive option for patients with advanced gastric cancer, improving their quality of life.
How similar studies have performed: While LECS has been used in case reports for palliative treatment, this is the first prospective trial investigating its use for advanced gastric cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * pT2-T4aN0M0 gastric carcinoma * Borrmann type 1-2 \< 5 cm or Borrmann type 3 \< 2 cm * Patient assessment by the multidisciplinary tumor board as not fit for gastrectomy * Signed informed consent Exclusion Criteria: * Borrman type 4 * Location in the cardia
Where this trial is running
Stockholm
- Karolinska University Hospital — Stockholm, Sweden (Recruiting)
Study contacts
- Principal investigator: Ioannis Rouvelas, MD, PhD — ME Övre buk, Karolinska Universitetssjukhuset
- Study coordinator: Ioannis Rouvelas, MD, PhD
- Email: ioannis.rouvals@regionstockholm.se
- Phone: +46707976814
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.